Hematopoiesis News Volume 11.20 | May 26 2020

TOP STORY

S100A9 Links Inflammation and Repair in Myocardial Infarction

Researchers assessed cardiac function, hematopoietic response, and myeloid phagocyte dynamics in wild-type C57BL/6 mice with permanent coronary artery ligation, treated with the specific S100A9 blocker ABR-238901 for 7 or 21 days. [Circ Res] Abstract

(Ranked by impact factor of the journal)

Temporal Expression of MOF Acetyltransferase Primes Transcription Factor Networks for Erythroid Fate

The authors explored the mechanism by which histone H4 lysine 16 acetyltransferase MOF regulates erythropoiesis. Single-cell RNA sequencing and chromatin immunoprecipitation sequencing uncovered that MOF influenced erythroid trajectory by dynamic recruitment to chromatin and its haploinsufficiency caused accumulation of a transient HSC population. [Sci Adv] Abstract

Specific, Targetable Interactions with the Microenvironment Influence Imatinib-Resistant Chronic Myeloid Leukemia

Scientists showed in various models, that murine and human imatinib-resistant leukemia cells positive for the oncogene BCR-ABL1T315I differed from BCR-ABL1 native cells with regards to niche location and specific niche interactions. [Leukemia] Full Article

Novel HDAC Inhibitor MAKV-8 and Imatinib Synergistically Kill Chronic Myeloid Leukemia Cells via Inhibition of BCR-ABL/MYC-Signaling: Effect on Imatinib Resistance and Stem Cells

Considering the specific upregulation of selected histone deacetylases in leukemia stem cells from chronic myeloid leukemia (CML) patients, the authors investigated the differential toxicity of a co-treatment with MAKV-8 and imatinib in CML versus healthy cells. [Clin Epigenetics] Full Article

A Small Molecule Compound IX Inhibits Telomere and Attenuates Oncogenesis of Drug‐Resistant Leukemia Cells

Investigators identified a novel compound IX, an imatinib derivative with a replacement fragment of a telomerase inhibitor, which could effectively eradicate leukemia stem cells but had no influence on normal HSC survival. [FASEB J] Full Article

Development of Small Molecule MEIS Inhibitors That Modulate HSC Activity

Researchers showed that small molecules named MEIS inhibitor (MEISi)-1 and MEISi-2 significantly inhibited MEIS-luciferase reporters in vitro and induced murine and human HSC self-renewal ex vivo. [Sci Rep] Full Article

A Biomathematical Model of Human Erythropoiesis and Iron Metabolism

Investigators developed a biomathematical model to simulate EPO- and iron medication in humans. They combined a previously established model of human erythropoiesis including comprehensive pharmacokinetic models of EPO applications with a newly developed model of iron metabolism including iron supplementation. [Sci Rep] Full Article

Phenotypic Analysis of the Mouse Hematopoietic Hierarchy Using Spectral Cytometry: From Stem Cell Subsets to Early Progenitor Compartments

The authors present a complex panel designed for spectral flow cytometry that allowed for the in‐depth analysis of the mouse hematopoietic stem and progenitor compartments. [Cytometry A] Abstract

Regulation of CD71⁺TER119⁺ Erythroid Progenitor Cells by CD45

Scientists showed that the leukocyte-specific tyrosine phosphatase, CD45 was down regulated in late erythroid development, yet it regulated the CD71⁺TER119⁺ progenitor pool, which included the Pro E, Ery A and Ery B populations. [Exp Hematol] Abstract

Combined G-CSF and Plerixafor Enhance Hematopoietic Recovery of CD34⁺ Cells from Poor Mobilizer Patients in NSG Mice

Investigators showed that mobilized-CD34⁺ cells recovered after G-CSF+Plerixafor mobilization protocol had an enhanced intrinsic hematopoietic reconstitution potential compared to CD34⁺ cells mobilized with G-CSF alone. [Exp Hematol] Abstract

Persistent DNA Damage-Induced NLRP12 Improves Hematopoietic Stem Cell Function

Scientists showed that persistent DNA damage-induced NOD-like receptor 12 (NLRP12) improved HSC function in both mouse and human models of DNA repair deficiency and aging. Specifically, treatment of Fanca^–/– mice with the DNA cross-linker mitomycin C or ionizing radiation induced NLRP12 upregulation in phenotypic HSCs. [JCI Insight] Full Article

CLINICAL RESEARCH

Eltrombopag Monotherapy Can Improve Hematopoiesis in Patients with Low to Intermediate Risk-1 Myelodysplastic Syndrome

Investigators conducted a Phase II dose modification study to investigate the safety and efficacy of eltrombopag in lower-risk-myelodysplastic syndrome. [Haematologica] Abstract

Subscribe to one of our other 19 science newsletters such as Cord Blood News & Cell Therapy News.

Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

The authors review the prevalence and characteristics of somatic alterations in aplastic anemia and paroxysmal nocturnal hemoglobinuria and explore their prognostic significance and mechanisms of clonal selection. [Blood] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma

Kleo Pharmaceuticals, Inc. and Celularity, Inc. announced a preclinical research collaboration to rapidly advance synergistic combinations of each company’s technology platform as potential treatments for COVID-19 and multiple myeloma. [Kleo Pharmaceuticals, Inc.] Press Release

Expression Therapeutics Announces IND Approval by the FDA for Hemophilia A Gene Therapy

Expression Therapeutics announced that it has received clearance by the FDA to proceed following review of its Investigational New Drug Application (IND) for clinical testing of its novel lentiviral vector-based gene therapy—ET3—for hemophilia A. [Expression Therapeutics (PR Newswire Association LLC.)] Press Release

US Lawmakers Unveil Bold $100 Billion Plan to Remake NSF

The National Science Foundation (NSF) would get a sweeping remake-including a new name, a huge infusion of cash, and responsibility for maintaining US global leadership in innovation-under bipartisan bills that have been introduced in both houses of Congress. [ScienceInsider] Editorial

Are Women Publishing Less during the Pandemic? Here’s What the Data Say

Early analyses suggest that female academics are posting fewer preprints and starting fewer research projects than their male peers. [Nature News] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW PhD Studentship – Erythropoiesis (University of Bristol)

Postdoctoral Fellowship – Hematopoiesis, Leukemia, and Bone Marrow Failure Syndromes (The University of Texas Southwestern Medical Center)

Postdoctoral Research Fellow – Hematologic Malignancy (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Molecular Hematology (Heidelberg University Hospital)

Postdoctoral Position – Tumor Immunology (University of Maryland)

Postdoctoral Position – Leukemia (Josep Carreras Leukaemia Research Institute)

Postdoctoral Position – Immunology/Molecular Biology (NIH National Heart, Lung, and Blood Institute)

Postdoctoral Associate – Hematopoiesis (The Jackson Laboratory)

PhD Position – Leukemic Stem Cells and Metabolism (University of Bern)

Postdoctoral Fellow – Hematopoiesis Research (Harvard Medical School)

Assistant/Associate Professor – Hematology & Oncology (UC Davis School of Medicine)

Associate/Professor – Hematology & Oncology (UC Davis School of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here.